Effect of Osimertinib and Bevacizumab on PFS of Patients With Metastatic EGFR-Mutant Lung Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial
JAMA Oncol 2020 May 28;[EPub Ahead of Print], HA Yu, AJ Schoenfeld, A Makhnin, R Kim, H Rizvi, D Tsui, C Falcon, B Houck-Loomis, F Meng, JL Yang, Y Tobi, G Heller, L Ahn, SA Hayes, RJ Young, ME Arcila, M Berger, JE Chaft, M Ladanyi, GJ Riely, MG KrisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.